Peptides & growth hormone

Argireline

Updated · 23 sources · Editorial policy

Argireline is the trade name of acetyl hexapeptide-8 (also sold as acetyl hexapeptide-3), a synthetic chain of six amino acids used in anti-wrinkle creams and serums. It was first described by Spanish researchers in 2002 as a copy of a small piece of SNAP-25, the nerve protein that botulinum toxin type A cuts. That is why it is described as a “Botox-like” ingredient and nicknamed “Botox in a jar” (Blanes-Mira et al., Int J Cosmet Sci 2002).

The key fact is that Argireline is a cosmetic ingredient, not a drug. In 2025 the US Cosmetic Ingredient Review (CIR) expert panel judged it safe in cosmetics only at concentrations up to 0.005%, and said the data were insufficient to call it safe above that level (Johnson et al., Int J Toxicol 2025). The clinical evidence is a handful of small, short studies with mixed results, and an FDA laboratory study found that almost none of it gets past the outer layers of the skin (Kraeling et al., Cutan Ocul Toxicol 2015).

This page summarizes what the laboratory studies, the small clinical trials and regulators report. It is for education only and is not medical advice.

Property Detail
Class Synthetic acetylated hexapeptide; “neurotransmitter-inhibiting” cosmetic peptide
Other names Acetyl hexapeptide-8 (cosmetic INCI name); acetyl hexapeptide-3; CAS 616204-22-9
Chemistry (PubChem) C₃₅H₆₂N₁₄O₁₁S, 887.0 g/mol
Proposed mechanism Mimics part of SNAP-25 and interferes with the SNARE complex that releases neurotransmitters (lab data)
Studied use in people Topical creams, serums and microneedle patches
Studied concentrations 0.005% in an NIH trial; one cosmetic trial used 10% of a solution containing 0.05% peptide
Half-life No published pharmacokinetic data
Skin penetration About 0.01% of the applied dose reached the living epidermis, none deeper (FDA lab study)
Regulatory status Listed EU cosmetic ingredient with no restrictions; CIR: safe up to 0.005%; not an approved drug
WADA status Not named on the 2026 list

What it is

Argireline is a hexapeptide, meaning a chain of six amino acids. One end is capped with an acetyl group and the other with an amide group. The EU cosmetic ingredient database describes it as a synthetic peptide made of arginine, methionine and acetylated glutamic acid residues (European Commission CosIng). PubChem lists the formula C₃₅H₆₂N₁₄O₁₁S, a molecular weight of 887.0 g/mol, and synonyms including acetyl hexapeptide-3, acetyl hexapeptide-8 and CAS 616204-22-9 (PubChem CID 71587772).

The sequence is copied from the N-terminal (starting) end of SNAP-25 (Wang et al., Am J Clin Dermatol 2013). It came out of a “rational design” program reported by a group at Miguel Hernández University in Alicante, Spain (Blanes-Mira et al., Int J Cosmet Sci 2002). The ingredient is sold under the Argireline name by Lipotec, a company in the same group as BCN Peptides (Lungu et al., Eur J Neurol 2013; Zdrada-Nowak et al., Int J Mol Sci 2025).

The peptide contains one methionine, an amino acid that oxidizes easily. A lab analysis of commercial creams and serums found both intact and oxidized Argireline, identified the methionine as the point of oxidation, and raised the question of how other ingredients affect the peptide’s stability in a product (Kluczyk et al., Chem Biodivers 2021).

Related cosmetic peptides in the library:

Peptide Relation to Argireline
Snap-8 (acetyl octapeptide-3) A longer, eight-amino-acid version built on the same SNAP-25 segment
GHK-Cu (copper tripeptide-1) A naturally occurring copper peptide; proposed to work on skin repair and collagen, not on nerve signals

The proposed mechanism

When a nerve tells a muscle to contract, small sacs (vesicles) inside the nerve ending release the messenger acetylcholine. To do this, each vesicle must dock with and fuse into the cell membrane, a step driven by a group of proteins called the SNARE complex. SNAP-25 is one of them. Botulinum toxin type A causes paralysis by cutting SNAP-25, which blocks acetylcholine release at the junction between nerve and muscle (Poras et al., Appl Environ Microbiol 2009).

The idea behind Argireline is that a decoy copy of part of SNAP-25 competes with the real protein, so fewer SNARE complexes form, less messenger is released and the muscles that crease the skin contract less. In laboratory tests, the developers found that Argireline interfered with the formation or stability of the SNARE complex and inhibited neurotransmitter release with a potency similar to botulinum toxin A, though, as expected, with much lower maximum effect (Blanes-Mira et al., Int J Cosmet Sci 2002). An independent group confirmed that Argireline reduced glutamate release from neurons grown in cell culture (Lim et al., Sci Rep 2018).

These are test-tube and cell-culture results. No study has shown that a cream containing Argireline reduces muscle activity in people.

How it behaves in the skin

For a “Botox-like” cream to work as claimed, the peptide must cross the skin and reach nerve endings in the muscle underneath. The available data suggest that it does not get that far.

An FDA laboratory applied an emulsion containing 10% Argireline (2 mg/cm²) to human cadaver skin and hairless guinea pig skin in diffusion cells for 24 hours (Kraeling et al., Cutan Ocul Toxicol 2015):

Where the peptide was found (% of applied dose) Human skin Guinea pig skin
Washed off the surface Most of the dose Most of the dose
Stratum corneum (outer dead layer) 0.22% 0.54%
Living epidermis 0.01% 0.01%
Dermis or fluid beneath the skin None detected None detected

Other laboratory work points the same way:

  • Size and charge. Argireline is large and water-loving, and it carries both positive and negative charges (a zwitterion), which hinders skin permeation (Lim et al., Sci Rep 2018).
  • The vehicle matters. In pig ear skin, water-rich emulsions delivered more peptide into the skin than an oil-rich one, and a multiple water-in-oil-in-water emulsion delivered the most (Hoppel et al., Eur J Pharm Sci 2015).
  • Review conclusion. A 2025 review concluded that the peptide appears to enter the epidermis but has a low chance of reaching the dermis, so delivering it through the skin to paralyze muscle is “likely impossible.” The authors suggest that any cosmetic effect may come from a different mechanism within the epidermis (Zdrada-Nowak et al., Int J Mol Sci 2025).

No study has measured Argireline’s half-life, absorption into the blood, or breakdown in people. In the FDA study, no breakdown product of the peptide was detected in any skin layer.

Regulatory status

  • European Union. Acetyl hexapeptide-8 is listed in the EU cosmetic ingredient database (CosIng) with the functions “humectant” and “skin conditioning.” No restriction, annex entry or maximum concentration is recorded (European Commission CosIng).
  • United States. Cosmetic ingredients, apart from color additives, do not need FDA approval before sale. FDA notes that a product intended to affect the structure or any function of the body meets the legal definition of a drug, and that the term “cosmeceutical” has no meaning under the law (FDA). The only medical use studied, eyelid spasm, was tested under an FDA investigational new drug application; it has not led to an approved drug (Lungu et al., Eur J Neurol 2013).
  • CIR safety review. The CIR expert panel concluded in 2025 that acetyl hexapeptide-8 (amide) is safe in cosmetics at concentrations up to 0.005%. It found the data insufficient to support safety above 0.005% (Johnson et al., Int J Toxicol 2025).
  • Sport. Argireline is not named on the WADA Prohibited List. Section S0 bans pharmacological substances not covered elsewhere on the list that have no current government approval for human therapeutic use; the list does not address cosmetic ingredients specifically (WADA 2026 Prohibited List).

What “10% Argireline” means. Several studies and product labels give Argireline as “10%.” In at least one trial this meant adding 10% of a commercial solution that itself contained 0.05% acetyl hexapeptide-3 (Tadini et al., Braz J Pharm Sci 2015). The NIH blepharospasm trial used 0.005% peptide, the same ceiling the CIR panel later set. Percentages on labels and in papers are therefore not always comparable.

What the research shows

Wrinkle studies of Argireline alone

Study Design and n Product and use Duration Result
Blanes-Mira et al., 2002 Developer study in healthy women; no control group described in the abstract Emulsion with 10% of the hexapeptide 30 days Wrinkle depth reduced by up to 30% (skin topography)
Wang et al., 2013 Randomized, placebo-controlled; n = 60, allocated 3:1 Argireline to placebo Applied to eye-area wrinkles twice daily 4 weeks Global “anti-wrinkle efficacy” 48.9% vs 0% with placebo; roughness on skin replicas fell with Argireline (p under 0.01) but not with placebo
Tadini et al., 2015 Vehicle-controlled, randomized application sites; 40 women aged 35–55 Cream with vs without acetyl hexapeptide-3, daily 4 weeks Reduced anisotropy (direction-dependent stiffness) of facial skin; no significant effect on viscoelasticity; hydration rose with all creams, including the vehicle
Raikou et al., 2017 Randomized, four groups; n = 24 Acetyl hexapeptide-3, tripeptide-10 citrulline, both, or neither 60 days Some between-group differences in skin roughness and water loss through the skin at days 20–60
Henseler, 2023 Double-blind, split-face; 19 women Hyaluronic acid serum with vs without Argireline, twice daily 4 weeks No significant difference between the Argireline side and the control side in wrinkle score (p = 0.829) or camera-estimated skin age

The largest placebo-controlled trial (Wang, n = 60) was positive, but its main outcome was a subjective global rating, only a quarter of participants received placebo, and the abstract does not report a direct statistical comparison between groups for the replica measurements. An independent double-blind split-face study with camera-based analysis (Henseler) found no effect of Argireline. The Henseler author concluded that Argireline should not be regarded as an alternative to botulinum toxin.

None of these studies measured muscle activity. A 2025 review noted that the in vivo studies assessed surface features of the skin and did not confirm that the peptide inhibits muscle contraction (Zdrada-Nowak et al., Int J Mol Sci 2025).

Multi-ingredient products and microneedle patches

Study Design and n Product Result
An et al., Ann Dermatol 2019 Double-blind, randomized, split-face; 52 women enrolled, 50 completed Cross-linked hyaluronic acid microneedle patch with acetyl hexapeptide-8, applied 4 h once a week for 29 days Greater wrinkle improvement than the plain microneedle patch (p under 0.05); no serious adverse effects
Zhu et al., Int J Cosmet Sci 2026 Two clinical studies (n = 50 and n = 42) by L’Oréal researchers; no vehicle group described in the abstract Serum with acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria (seaweed) extract Static wrinkle scores improved 35–69% and dynamic wrinkle scores 10–13% at 12 weeks

Microneedle patches pierce the outer skin layer, so their results do not show what a standard cream does. The serum studies cannot isolate Argireline’s contribution, because the product combined several active ingredients and was not compared with a vehicle.

Blepharospasm: the one medical trial

Blepharospasm is involuntary, forceful closure of the eyelids, usually treated with botulinum toxin injections every few months. An NIH team ran a double-blind, randomized, placebo-controlled pilot in 24 patients, who applied a 0.005% acetyl hexapeptide-8 cream or placebo to the eyelids twice daily after their usual toxin injection (Lungu et al., Eur J Neurol 2013):

  • Time until symptoms returned to baseline: 3.7 months with the peptide vs 3.0 months with placebo, a trend that was not statistically significant.
  • 4 of 12 patients in the active group had a considerable extension of symptom control (3.3–7.1 months).
  • No severe adverse events occurred.

The authors called the result promising but noted that the concentration was probably too low and the sample too small. A peptide maker (BCN Peptides) supplied the creams and two of its staff were co-authors.

Animal studies

  • Mice, topical. In mice with chemically induced skin aging, Argireline applied twice daily for 6 weeks increased type I collagen and decreased type III collagen in the skin (Wang et al., J Cosmet Laser Ther 2013).
  • Rats, injected. In 40 rats given injections under the skin before a surgical skin-flap procedure, Argireline alone produced a collagen profile indistinguishable from saline, while botulinum toxin changed it. The authors concluded that injected Argireline had no detectable tissue-level effect (Acuner et al., Aesthetic Plast Surg 2026).

These results come from animals and cannot be assumed to apply to people.

Side effects and risks

Topical use

Topical Argireline has been well tolerated in the published studies, which were small and short:

  • The developers reported no oral toxicity and no primary skin irritation at high doses in their safety tests (Blanes-Mira et al., Int J Cosmet Sci 2002).
  • In the NIH blepharospasm trial, four patients had mild, self-limiting eyelid irritation or a feeling of “heaviness,” two on the peptide and two on placebo (Lungu et al., Eur J Neurol 2013).
  • The Henseler split-face study reported no significant adverse events, allergic reactions or skin irritation (Henseler, 2023).

The NIH trial report cites unpublished manufacturer toxicology data showing no topical or systemic toxicity at 0.05% and above. These data are not public. The CIR panel’s independent review supported safety only up to 0.005% (Johnson et al., Int J Toxicol 2025).

In cell culture, Argireline slowed cell growth in a dose-dependent way, but only at concentrations 18 to 10,000 times higher than the cancer drug doxorubicin used as a comparison, depending on the cell type (Grosicki et al., Acta Biochim Pol 2014).

Injection

Argireline is sometimes injected in aesthetic settings, but injection has not been studied in people: there are no dose-finding, efficacy or safety trials. The one controlled animal study found no tissue effect of injected Argireline.

A published case shows one concrete risk. A 45-year-old woman developed redness, nodules and abscesses at injection sites on her forehead and temples one week after Argireline injections. Cultures grew Mycobacterium abscessus, and she needed clarithromycin and moxifloxacin for 5 months before the lesions subsided (Chen et al., World J Clin Cases 2021). The authors noted that this infection is easily mistaken for a common bacterial infection.

Product quality

There is no published independent testing of how much intact peptide commercial products contain. The one analytical study found oxidized as well as intact Argireline in several cosmetics (Kluczyk et al., Chem Biodivers 2021).

Key takeaways

  • A cosmetic copy of part of SNAP-25. Argireline (acetyl hexapeptide-8, also called acetyl hexapeptide-3) is a six-amino-acid peptide designed to mimic the protein that botulinum toxin cuts.
  • The mechanism is shown only in the lab. It reduced neurotransmitter release in test-tube and cell studies, but no study has shown that a cream reduces muscle activity in people.
  • It barely enters the skin. In an FDA lab study, about 0.01% of the applied dose reached the living epidermis and none reached the dermis.
  • Mixed, small clinical studies. A 60-person trial reported a positive subjective rating after 4 weeks, but an independent blinded split-face study found no effect, and an NIH eyelid-spasm pilot showed only a non-significant trend.
  • A cosmetic ingredient, not a drug. It is an unrestricted EU cosmetic ingredient, and the US CIR panel considers it safe only up to 0.005%. Injection has no human safety data, and one case of serious mycobacterial infection after injection has been published.

Sources

  1. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303–310. PubMed.
  2. Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety assessment of acetyl hexapeptide-8 amide as used in cosmetics. Int J Toxicol. 2025;44(2 suppl):54S–63S. PubMed.
  3. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46–52. PubMed.
  4. European Commission. CosIng cosmetic ingredient database: Acetyl Hexapeptide-8 (substance ID 54135). European Commission.
  5. National Center for Biotechnology Information. PubChem Compound Summary for CID 71587772, Acetyl hexapeptide-8. PubChem.
  6. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147–153. PubMed.
  7. Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013;20(3):515–518. PubMed; PMC.
  8. Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl hexapeptide-8 in cosmeceuticals: a review of skin permeability and efficacy. Int J Mol Sci. 2025;26(12):5722. PubMed; PMC.
  9. Kluczyk A, Ludwiczak J, Modzel M, et al. Argireline: needle-free Botox as analytical challenge. Chem Biodivers. 2021;18(3):e2000992. PubMed.
  10. Poras H, Ouimet T, Orng SV, et al. Detection and quantification of botulinum neurotoxin type A by a novel rapid in vitro fluorimetric assay. Appl Environ Microbiol. 2009;75(13):4382–4390. PubMed.
  11. Lim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Sci Rep. 2018;8(1):1596. PubMed.
  12. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27–35. PubMed.
  13. US Food and Drug Administration. Is it a cosmetic, a drug, or both? (Or is it soap?). Content current as of September 11, 2024. FDA.
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 Prohibited List.
  15. Tadini KA, Mercurio DG, Campos PMBGM. Acetyl hexapeptide-3 in a cosmetic formulation acts on skin mechanical properties: clinical study. Braz J Pharm Sci. 2015;51(4):901–909. SciELO.
  16. Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017;16(2):271–278. PubMed.
  17. Henseler H. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia(®) Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW. 2023;12:Doc09. PubMed; PMC.
  18. An JH, Lee HJ, Yoon MS, Kim DH. Anti-wrinkle efficacy of cross-linked hyaluronic acid-based microneedle patch with acetyl hexapeptide-8 and epidermal growth factor on Korean skin. Ann Dermatol. 2019;31(3):263–271. PubMed.
  19. Zhu M, He X, Zhu Z, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: ex vivo and clinical studies. Int J Cosmet Sci. 2026;48(5):913–925. PubMed.
  20. Wang Y, Wang M, Xiao XS, Huo J, Zhang WD. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013;15(4):237–241. PubMed.
  21. Acuner B, Görgülü T, Işıktekin E, Kaymaz Morkoç E, Kargı AE. Effects of botulinum toxin type A and Argireline on dermal collagen remodeling and skin biology in a flap model. Aesthetic Plast Surg. Published online August 31, 2026. PubMed.
  22. Grosicki M, Latacz G, Szopa A, Cukier A, Kieć-Kononowicz K. The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochim Pol. 2014;61(1):29–32. PubMed.
  23. Chen CF, Liu J, Wang SS, Yao YF, Yu B, Hu XP. Mycobacterium abscessus infection after facial injection of argireline: a case report. World J Clin Cases. 2021;9(8):1996–2000. PubMed.